ACA

NEUTRALM&A

Arcosa, Inc.

2026-07-20

Price

$144.74

-0.19%

This is the 2026-07-20 snapshot — the signals and analysis for ACA as of this single trading day.

View full ACA research hub →

Score5.2Watchlist

Signals4/8 DNA2/13 Act · 1/4 Risk

SentimentNEUTRALScore: 8

Volume0.4xvs 20d avg

Analysis

Arcosa's (ACA) current price action is entirely dictated by its definitive agreement to be acquired by CRH for $150 per share in cash. The stock's tight consolidation, evidenced by a BOLLINGER_SQUEEZE and ultra-low 0.4x volume, reflects classic merger arbitrage behavior rather than organic technical breakouts. Despite the CAUTION macro regime and rising VIX from geopolitical tensions, exceptionally low credit spreads (0.79%) signal that financing for the $8.5B deal remains rock-solid, giving institutional arbitrageurs high conviction to absorb any market-wide volatility.

Fired Signals

ALPHA MALEGOLDEN CROSSBOLLINGER SQUEEZEPERFECT STACKPANIC REVERSALBARGAIN HUNTERDISTRIBUTION

Key Takeaways

The $150/share all-cash acquisition by CRH caps upside but provides a rigid floor, overriding the broader geopolitical CAUTION regime.
Technical indicators (PERFECT_STACK, BOLLINGER_SQUEEZE) are artifacts of M&A arbitrage, with the stock trading at a ~3.6% discount to the deal price.
The primary risk is regulatory or antitrust interference before the Q1 2027 expected closing, though stable credit markets support deal financing.

← Back to 2026-07-20 View Full ACA History →Yahoo Finance &nearr;